首页> 外文期刊>The pharmacogenomics journal >Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS)
【24h】

Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS)

机译:化疗后膜转运基因遗传多态性遗传多态性的关联:宫乳腺癌研究中的荟萃分析和寻找(SEBCS)

获取原文
获取原文并翻译 | 示例
       

摘要

Membrane transporters can be major determinants of the pharmacokinetic profiles of anticancer drugs. The associations between genetic variations of ATP-binding cassette (ABC) and solute carrier (SLC) genes and cancer survival were investigated through a meta-analysis and an association study in the Seoul Breast Cancer Study (SEBCS). Including the SEBCS, the meta-analysis was conducted among 38 studies of genetic variations of transporters on various cancer survivors. The population of SEBCS consisted of 1338 breast cancer patients who had been treated with adjuvant chemotherapy. A total of 7750 SNPs were selected from 453 ABC and/or SLC genes typed by an Affymetrix 6.0 chip. ABCB1 rs1045642 was associated with poor progression-free survival in a meta-analysis (HR = 1.33, 95% CI: 1.07-1.64). ABCB1, SLC8A1, and SLC12A8 were associated with breast cancer survival in SEBCS (P-gene 0.05). ABCB1 rs1202172 was differentially associated with survival depending on the chemotherapy (P-interaction = 0.035). Our finding provides suggestive associations of membrane transporters on cancer survival.
机译:膜转运蛋白可以是抗癌药物药代动力学谱的主要决定因素。通过在首尔乳腺癌研究(SEBCS)中,研究了ATP结合盒(ABC)和溶质载体(ABC)和溶质载体(SLC)基因(SLC)基因(SLC)基因和癌症存活的缔合物之间的缔合。包括SEBCS,在各种癌症幸存者上进行38项遗传变异的研究中进行了荟萃分析。 SEBC的人口由1338名乳腺癌患者组成,被佐剂化疗治疗。共选自7750个SNP,由Affymetrix 6.0芯片键入的453 ABC和/或SLC基因中选择。 ABCB1 rs1045642在META分析中与无进展生存期有关(HR = 1.33,95%CI:1.07-1.64)。 ABCB1,SLC8A1和SLC12A8与SEBCS中的乳腺癌存活相关(P-Gene <0.05)。根据化疗(P互动= 0.035),ABCB1 RS1202172与存活差异相关(p互动= 0.035)。我们的发现提供了膜转运蛋白对癌症存活的暗示联想。

著录项

  • 来源
    《The pharmacogenomics journal》 |2018年第5期|共13页
  • 作者单位

    Seoul Natl Univ Dept Biomed Sci Grad Sch Seoul South Korea;

    Seoul Natl Univ Dept Biomed Sci Grad Sch Seoul South Korea;

    Seoul Natl Univ Dept Biomed Sci Grad Sch Seoul South Korea;

    Seoul Natl Univ Dept Biomed Sci Grad Sch Seoul South Korea;

    Chonnam Natl Univ Coll Pharm Gwangju South Korea;

    Duksung Womens univ Coll Pharm Seoul South Korea;

    Seoul Natl Univ Canc Res Inst Seoul South Korea;

    Natl Evidence Based Healthcare Collaborating Agcy Div New Hlth Technol Assessment Seoul South;

    NCI Div Canc Epidemiol &

    Genet Bethesda MD 20892 USA;

    Seoul Natl Univ Canc Res Inst Seoul South Korea;

    Univ Ulsan Asan Med Ctr Dept Surg Coll Med Seoul South Korea;

    Seoul Natl Univ Dept Biomed Sci Grad Sch Seoul South Korea;

    Natl Canc Ctr Div Canc Epidemiol &

    Management Goyang South Korea;

    Seoul Natl Univ Canc Res Inst Seoul South Korea;

    Seoul Natl Univ Dept Prevent Med Coll Med Seoul South Korea;

    Seoul Natl Univ Dept Biomed Sci Grad Sch Seoul South Korea;

    Seoul Natl Univ Dept Biomed Sci Grad Sch Seoul South Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

  • 入库时间 2022-08-20 07:28:37

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号